Mannitol 20%, Bronchitol(mannitol)
Aridol, Bronchitol, Mannitol, Osmitrol (mannitol) is a small molecule pharmaceutical. Mannitol was first approved as Mannitol 20% on 1982-01-01. It is used to treat anuria, brain edema, ocular hypertension, and oliguria in the USA. It has been approved in Europe to treat cystic fibrosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Aridol, Bronchitol, Osmitrol (generic drugs available since 1982-01-01, discontinued: Resectisol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mannitol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MANNITOL 5% IN PLASTIC CONTAINER | B. Braun Medical | N-020006 RX | 1993-07-26 | 1 products |
| MANNITOL 10% IN PLASTIC CONTAINER | B. Braun Medical | N-020006 RX | 1993-07-26 | 1 products |
| MANNITOL 15% IN PLASTIC CONTAINER | B. Braun Medical | N-020006 RX | 1993-07-26 | 1 products |
| MANNITOL 20% IN PLASTIC CONTAINER | B. Braun Medical | N-020006 RX | 1993-07-26 | 1 products |
| OSMITROL 5% IN WATER | Baxter | N-013684 RX | 1982-01-01 | 1 products |
| OSMITROL 10% IN WATER | Baxter | N-013684 RX | 1982-01-01 | 1 products |
| OSMITROL 20% IN WATER | Baxter | N-013684 RX | 1982-01-01 | 1 products |
| OSMITROL 15% IN WATER | Baxter | N-013684 RX | 1982-01-01 | 1 products |
| OSMITROL 5% IN WATER IN PLASTIC CONTAINER | Baxter | N-013684 RX | 1982-01-01 | 1 products |
| OSMITROL 10% IN WATER IN PLASTIC CONTAINER | Baxter | N-013684 RX | 1982-01-01 | 1 products |
Show 6 marketed
Show 22 discontinued
Mannitol
+
Sorbitol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SORBITOL-MANNITOL IN PLASTIC CONTAINER | ICU Medical | N-018316 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aridol bronchial challenge test kit | New Drug Application | 2023-02-13 |
| bronchitol | New Drug Application | 2024-09-03 |
| curestem cell healer c10 program | unapproved drug other | 2020-06-08 |
| curestem cell healer c20 | unapproved drug other | 2020-06-05 |
| curestem cell healer c5 program | unapproved drug other | 2020-06-05 |
| gd11 rx scm c5 | unapproved drug other | 2017-08-24 |
| leuprolide acetate depot | New Drug Application | 2024-08-27 |
| mannitol | New Drug Application | 2024-01-27 |
| osmitrol | New Drug Application | 2018-11-15 |
| sorbitol-mannitol | New Drug Application | 2021-04-07 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MANNITOL, BRONCHITOL, CHIESI | |||
| 2027-10-30 | ODE-327 | ||
| 2023-10-30 | NP | ||
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A06: Drugs for constipation
— A06A: Drugs for constipation
— A06AD: Osmotically acting laxatives
— A06AD16: Mannitol
B: Blood and blood forming organ drugs
— B05: Blood substitutes and perfusion solutions
— B05B: Iv solutions used in parenteral administration of fluids, electrolytes and nutrients
— B05BC: Solutions producing osmotic diuresis
— B05BC01: Mannitol
— B05C: Irrigating solutions, blood substitutes and perfusion
— B05CX: Other irrigating solutions in atc
— B05CX04: Mannitol
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05C: Expectorants, excl. combinations with cough suppressants
— R05CB: Mucolytics
— R05CB16: Mannitol
V: Various drug classes in atc
— V04: Diagnostic agents
— V04C: Other diagnostic agents in atc
— V04CX: Other diagnostic agents in atc
— V04CX04: Mannitol
Clinical
Clinical Trials
477 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 4 | 4 | 7 | 13 | 30 |
| Intracranial hypertension | D019586 | EFO_1000992 | — | 1 | 1 | 4 | 2 | 9 | 16 |
| Fibrosis | D005355 | — | — | 4 | 5 | 4 | 1 | 1 | 15 |
| Brain injuries | D001930 | — | S06.9 | 1 | 2 | 4 | 2 | 6 | 13 |
| Infections | D007239 | EFO_0000544 | — | 2 | 5 | 5 | 1 | 1 | 12 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 3 | 5 | 3 | 1 | — | 12 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | 2 | 3 | 2 | 5 | 11 |
| Syndrome | D013577 | — | — | 2 | 2 | 1 | 2 | 5 | 11 |
| Brain edema | D001929 | EFO_1000845 | G93.6 | 2 | 2 | — | 2 | 6 | 11 |
| Communicable diseases | D003141 | — | — | 1 | 4 | 5 | 1 | — | 10 |
Show 59 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 2 | 3 | 5 | — | 3 | 13 |
| Glioblastoma | D005909 | EFO_0000515 | — | 7 | 5 | 1 | — | 2 | 11 |
| Covid-19 | D000086382 | — | — | — | 4 | 8 | — | — | 10 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 5 | — | 1 | 8 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 3 | 1 | — | 2 | 7 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 4 | 2 | — | — | 7 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 2 | 4 | — | 1 | 7 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 2 | 3 | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | 1 | — | 1 | 5 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | 1 | — | 2 | 5 |
Show 86 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 33 | 3 | — | — | 4 | 39 |
| Neoplasms | D009369 | — | C80 | 6 | 8 | — | — | 3 | 12 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 2 | — | — | 6 | 9 |
| Astrocytoma | D001254 | EFO_0000271 | — | 6 | 4 | — | — | — | 7 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | 5 | 7 |
| Carcinoma | D002277 | — | C80.0 | 2 | 3 | — | — | 1 | 6 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 2 | 2 | — | — | 2 | 6 |
| Central nervous system neoplasms | D016543 | — | — | 6 | 4 | — | — | — | 6 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | 5 | 6 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 2 | 2 | — | — | — | 4 |
Show 117 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | 3 | 4 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 2 | — | — | — | 2 | 4 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | 1 | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
| Phenylketonurias | D010661 | — | E70.0 | 2 | — | — | — | — | 2 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 1 | — | — | — | — | 1 |
| Hyperlipoproteinemia type iv | D006953 | Orphanet_413 | E78.1 | 1 | — | — | — | — | 1 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | — | — | — | — | 1 |
| Familial combined hyperlipidemia | D006950 | EFO_0000492 | E78.49 | 1 | — | — | — | — | 1 |
Show 27 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 8 | 8 |
| Cardiac surgical procedures | D006348 | — | — | — | — | — | — | 4 | 4 |
| Cutis laxa | D003483 | — | Q82.8 | — | — | — | — | 4 | 4 |
| Supratentorial neoplasms | D015173 | — | C71.0 | — | — | — | — | 4 | 4 |
| Acute liver failure | D017114 | HP_0004448 | — | — | — | — | — | 3 | 3 |
| Middle cerebral artery infarction | D020244 | EFO_1001045 | G46.0 | — | — | — | — | 3 | 3 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 3 | 3 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 2 | 2 |
| Memory | D008568 | — | — | — | — | — | — | 2 | 2 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | — | — | — | — | 2 | 2 |
Show 79 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mannitol |
| INN | — |
| Description | D-mannitol is the D-enantiomer of mannitol. It has a role as an osmotic diuretic, a sweetening agent, an antiglaucoma drug, a metabolite, an allergen, a hapten, a food bulking agent, a food anticaking agent, a food humectant, a food stabiliser, a food thickening agent, an Escherichia coli metabolite and a member of compatible osmolytes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mannitol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 86,144 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aridol bronchial challenge test kit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,370 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use